Ontology highlight
ABSTRACT: Introduction
Despite years of research, there are no disease-modifying drugs for Alzheimer's disease (AD), a fatal, age-related neurodegenerative disorder. Screening for potential therapeutics in rodent models of AD has generally relied on testing compounds before pathology is present, thereby modeling disease prevention rather than disease modification. Furthermore, this approach to screening does not reflect the clinical presentation of AD patients which could explain the failure to translate compounds identified as beneficial in animal models to disease modifying compounds in clinical trials. Clearly a better approach to pre-clinical drug screening for AD is required.Methods
To more accurately reflect the clinical setting, we used an alternative screening strategy involv
SUBMITTER: Prior M
PROVIDER: S-EPMC3706879 | biostudies-literature | 2013
REPOSITORIES: biostudies-literature